Clinicopathological findings, treatment, and outcome in 60 cats with gastrointestinal eosinophilic sclerosing fibroplasia.
eosinophilia
gastrointestinal mass
mesenteric mass
ragdoll
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
received:
20
02
2023
accepted:
02
01
2024
medline:
11
1
2024
pubmed:
11
1
2024
entrez:
11
1
2024
Statut:
aheadofprint
Résumé
Gastrointestinal eosinophilic sclerosing fibroplasia (GESF) in cats presents as mass(es) associated with the gastrointestinal tract, mesentery, and abdominal lymph nodes. To report the clinicopathological findings, treatment, and outcome of cats with GESF. Sixty client-owned cats diagnosed with GESF. Retrospective review of medical records of cats with histopathologically confirmed GESF. The median age was 5.4 years (interquartile range [IQR], 3.3-8.9.); 30% were Domestic Shorthairs and 12% were Domestic Longhair cats, with the most prevalent pedigree breeds being Ragdolls (25%), Exotic Shorthair (10%) and Persian (8%) cats. The median duration of clinical signs was 90 days (IQR, 17.5-247.0); the most common clinical signs were weight loss (60%), hyporexia/anorexia (55%), chronic vomiting (37%), lethargy (35%) and chronic diarrhea (27%). Masses were located in the small intestine (32%), stomach (27%), ileocolic junction (15%), colon (10%), lymph node (8%) and mesentery (8%) and 15% of cats had >1 mass. Eosinophilia was present in 50% and hypoalbuminemia in 28% of cats. The mass was removed surgically in 37% of cases. Most cats (98%) were treated with corticosteroids. Survival was not statistically different between cats treated with surgical resection and cats treated with medical therapy alone, 88% of the cats were still alive at the time of writing. GESF is an important differential diagnosis for abdominal masses in cats, and has a much better prognosis than previously reported.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal eosinophilic sclerosing fibroplasia (GESF) in cats presents as mass(es) associated with the gastrointestinal tract, mesentery, and abdominal lymph nodes.
HYPOTHESIS/OBJECTIVES
OBJECTIVE
To report the clinicopathological findings, treatment, and outcome of cats with GESF.
ANIMALS
METHODS
Sixty client-owned cats diagnosed with GESF.
METHODS
METHODS
Retrospective review of medical records of cats with histopathologically confirmed GESF.
RESULTS
RESULTS
The median age was 5.4 years (interquartile range [IQR], 3.3-8.9.); 30% were Domestic Shorthairs and 12% were Domestic Longhair cats, with the most prevalent pedigree breeds being Ragdolls (25%), Exotic Shorthair (10%) and Persian (8%) cats. The median duration of clinical signs was 90 days (IQR, 17.5-247.0); the most common clinical signs were weight loss (60%), hyporexia/anorexia (55%), chronic vomiting (37%), lethargy (35%) and chronic diarrhea (27%). Masses were located in the small intestine (32%), stomach (27%), ileocolic junction (15%), colon (10%), lymph node (8%) and mesentery (8%) and 15% of cats had >1 mass. Eosinophilia was present in 50% and hypoalbuminemia in 28% of cats. The mass was removed surgically in 37% of cases. Most cats (98%) were treated with corticosteroids. Survival was not statistically different between cats treated with surgical resection and cats treated with medical therapy alone, 88% of the cats were still alive at the time of writing.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
GESF is an important differential diagnosis for abdominal masses in cats, and has a much better prognosis than previously reported.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Craig L, Hardam E, Hertzke D, et al. Feline gastrointestinal eosinophilic sclerosing fibroplasia. Vet Pathol. 2009;46:63-70.
Linton M, Nimmo JS, Norris JM, et al. Feline gastrointestinal eosinophilic sclerosing fibroplasia: 13 cases and review of an emerging clinical entity. J Feline Med Surg. 2015;17:392-404.
Kambe N, Okabe R, Osada H, et al. A case of feline gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery. J Small Anim Pract. 2020;61:64-67.
Thieme ME, Olsen AM, Woolcock AD, Miller MA, Simons MC. Diagnosis and management of a case of retroperitoneal eosinophilic sclerosing fibroplasia in a cat. J Feline Med Surg Open Rep. 2019;5:2055116919867178.
Zampieri B, Church ME, Walsh K, Lennon EM. Feline eosinophilic sclerosing fibroplasia-a characteristic inflammatory response in sites beyond the gastrointestinal tract: case report and proposed nomenclature. J Feline Med Surg Open Rep. 2022;8:20551169221117516.
Munday J, Martinez A, Soo M. A case of feline gastrointestinal eosinophilic sclerosing fibroplasia mimicking metastatic neoplasia. N Z Vet J. 2014;62:356-360.
Gamble DA. Letters to the editor and rebuttal regarding the paper recently published in Veterinary and Comparative Oncology, ‘Feline intestinal sclerosing mast cell tumour: 50 cases (1997-2008) 2010; 8: 72-79’ by CHC Halsey, BE Powers and DA Kamstock. Letter to the editor# 2. Vet Comp Oncol. 2010;8:235-242.
Schulman FY, Lipscomb TP. Letters to the editor and rebuttal regarding the paper recently published in Veterinary and Comparative Oncology, ‘Feline intestinal sclerosing mast cell tumour: 50 cases (1997-2008) 2010; 8: 72-79’ by C. H. C. Halsey, B. E. Powers and D. A. Kamstock. Letter to the editor #1. Vet Comp Oncol. 2010;8:234-235. author reply 236-242.
Porras N, Rebollada-Merino A, Rodríguez-Franco F, Calvo-Ibbitson A, Rodríguez-Bertos A. Feline gastrointestinal eosinophilic sclerosing fibroplasia-extracellular matrix proteins and TGF-β1 immunoexpression. Vet Sci. 2022;9:291.
Cho M-J, Kim M-C, Seo K-W. Feline gastrointestinal eosinophilic sclerosing fibroplasia in a Bengal cat. J Vet Clin. 2017;34:481-483.
Montenegro NE, Castro DAR, López PAB, et al. Feline gastrointestinal eosinophilic sclerosing fibroplasia. Braz J Vet Pathol. 2022;15:57-61.
Suzuki M, Onchi M, Ozaki M. A case of feline gastrointestinal eosinophilic sclerosing fibroplasia. J Toxicol Pathol. 2013;26:51-53.
Agulla B, Díaz-Regañón D, García-Sancho M, et al. Remission of feline gastrointestinal eosinophilic sclerosing fibroplasia in a cat treated with corticotherapy. Pakistan Vet J. 2021;41:309-312.
Kim M-s, Kim K, Lee G-h, et al. Successful management of feline gastrointestinal eosinophilic sclerosing fibroplasia with mycophenolate mofetil and prednisolone following surgical resection in a cat. Thai J Vet Med. 2021;51:773-777.
Takao K, Saitoh S, Nibe K. Surgical treatment of feline gastrointestinal eosinophilic sclerosing fibroplasia in a cat. Jpn J Vet Anesth Surg. 2015;46:81-82.
Weissman A, Penninck D, Webster C, Hecht S, Keating J, Craig LE. Ultrasonographic and clinicopathological features of feline gastrointestinal eosinophilic sclerosing fibroplasia in four cats. J Feline Med Surg. 2013;15:148-154.
Brloznik M, Faraguna S, Goc M, Svara T. Recurrent feline gastrointestinal eosinophilic sclerosing fibroplasia and presumptive eosinophilic cystitis in a domestic short-haired cat: a case report. Vet Med. 2017;62:295-300.
Ozaki K, Yamagami T, Nomura K, Haritani M, Tsutsumi Y, Narama I. Abscess-forming inflammatory granulation tissue with Gram-positive cocci and prominent eosinophil infiltration in cats: possible infection of methicillin-resistant Staphylococcus. Vet Pathol. 2003;40:283-287.
Pesteanu-Somogyi LD, Radzai C, Pressler BM. Prevalence of feline infectious peritonitis in specific cat breeds. J Feline Med Surg. 2006;8:1-5.
Grau-Roma L, Galindo-Cardiel I, Isidoro-Ayza M, Fernández M, Majó N. A case of feline gastrointestinal eosinophilic sclerosing fibroplasia associated with phycomycetes. J Comp Pathol. 2014;151:318-321.